Everolimus

Generic Name: Everolimus

Brand Names: Afinitor, Votubia, Zortress

Drug Type: Small Molecule

Chemical Formula: C_₅₃H_₈₃NO_₁₄

CAS Number: 159351-69-6

Unique Ingredient Identifier: 9HW64Q8G6G

Background: Everolimus is a derivative of Rapamycin (sirolimus), and works similarly to Rapamycin as an mTOR (mammalian target of rapamycin) inhibitor. It is currently used as an immunosuppressant to prevent rejection of organ transplants. In a similar fashion to other mTOR inhibitors Everolimus' effect is solely on the mTORC1 protein and not on the mTORC2 protein.

Indication: Everolimus is indicated for the treatment of postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer (advanced HR+ BC) in combination with exemestane, after failure of treatment with letrozole or anastrozole.
...

Associated Conditions: Heart Transplant Rejection, Kidney Transplant Rejection, Liver Transplant Rejection, Progressive Neuroendocrine Tumors of pancreatic origin, Renal angiomyolipoma, tuberous sclerosis complex, Subependymal giant cell astrocytoma, tuberous sclerosis complex, Waldenstrom's Macroglobulinemia Refractory, Advanced Carcinoid tumor, Locally advanced Progressive Neuroendocrine Tumors of gastrointestinal origin, Locally advanced lung origin Progressive Neuroendocrine Tumors, Metastatic gastrointestinal origin Progressive Neuroendocrine Tumors, Metastatic lung origin Progressive Neuroendocrine Tumors, Refractory Advanced Renal Cell Carcinoma, Refractory, advanced Breast cancer, Unresectable gastrointestinal origin Progressive Neuroendocrine Tumors, Unresectable lung origin Progressive Neuroendocrine Tumors

Associated Therapies: -

Clinical Trials

Everolimus and Bortezomib in Treating Patients With Relapsed or Refractory Lymphoma

Phase 1

Terminated

Conditions: 714leukemia
Lymphoma

Interventions: Drug: Bortezomib
Drug: Everolimus

First Posted Date: 2008-05-05

Last Posted Date: 2015-10-28

Lead Sponsor: Brian Hill, MD, PhD

Target Recruit Count: 30

Registration Number: NCT00671112

Locations: 🇺🇸
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

Concentration Controlled Everolimus With Reduced Dose Cyclosporine Versus Mycophenolate Mofetil With Standard Dose Cyclosporine in de Novo Renal Transplant Adult Recipients Treated With Basiliximab and Corticosteroids

Phase 3

Completed

Conditions: Kidney Transplantation

Interventions: Drug: Mycophenolate mofetil (MMF)
Drug: Everolimus
Drug: Basiliximab
Drug: Cyclosporine A
Drug: Corticosteroid

First Posted Date: 2008-04-15

Last Posted Date: 2013-06-21

Lead Sponsor: Novartis

Target Recruit Count: 122

Registration Number: NCT00658320

Locations: 🇯🇵
Novartis Pharma K.K., Japan, Tokyo, Japan

Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors

Phase 1

Completed

Conditions: Stage IV Renal Cell Cancer
Thyroid Gland Medullary Carcinoma
Unspecified Adult Solid Tumor, Protocol Specific
Gastrinoma
Insulinoma
Metastatic Gastrointestinal Carcinoid Tumor
Metastatic Pheochromocytoma
Recurrent Gastrointestinal Carcinoid Tumor
Stage III Neuroendocrine Carcinoma of the Skin
Stage IV Melanoma

Interventions: Drug: everolimus
Drug: vatalanib
Other: pharmacological study
Other: laboratory biomarker analysis
Procedure: dynamic contrast-enhanced magnetic resonance imaging
Procedure: ultrasound imaging

First Posted Date: 2008-04-10

Last Posted Date: 2024-08-21

Lead Sponsor: Mayo Clinic

Target Recruit Count: 96

Registration Number: NCT00655655

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

Expanded Access Study of RAD001 in Metastatic Renal Cell Cancer Patients Who Are Intolerant of or Who Have Failed Despite Prior Vascular Endothelial Growth Factor Therapy

Conditions: Metastatic Renal Cell Cancer

First Posted Date: 2008-04-09

Last Posted Date: 2011-08-19

Lead Sponsor: Novartis Pharmaceuticals

Registration Number: NCT00655252

Locations: 🇺🇸
The Cancer Institute, St. Joseph Medical Center, Towson, Maryland, United States
🇺🇸
Indiana University Cancer center, Indianapolis, Indiana, United States
🇺🇸
Cliveland Clinic Foundation, Cleveland, Ohio, United States

and more 37 locations